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ABSTRACT 
Objective: Out of various cancer types, Breast and ovarian cancers are the most commonly occurring malignancies in women. As per literature, a 
large number of mutations are reported in various mitochondrial genome encoded subunits of respiratory chain complexes in breast and ovarian 
cancer patients. However, a very few of them are functionally validated till now. Our study is an attempt to highlight the pathogenic potential of all 
these reported mutations in breast and ovarian cancer patients. 
Methods: In order to achieve so, total 109mitochondrial gene mutations of breast cancer and 11 mitochondrial gene mutations of ovarian cancer 
patients were selected from MITOMAP database as well as various literatures. All these mutations were analyzed using various in silico tools such as 
MUSCLE, PolyPhen-2, SIFT, Mut Pred, Mu Pro, PANTHER, GOR4 and MUSCLE. 
Results: As a result of our analysis, 28 out 95 mutations in CytB gene are most pathogenic in the case of breast cancer patients. On the other hand 2 
out of 3 mutations of the same gene were predicted to be potentially pathogenic in case of ovarian cancer patients. Mutations in other mitochondrial 
subunit was also predicted pathogenic but with the low score. 
Conclusion: Out of different mitochondrial subunits, CytB seems to most important site for mutations in these two groups of patients. Hence, 
mutations of CytB subunit, which are predicted to be highly pathogenic as per our analysis, should be functionally validated in future. 
Keywords: Mitochondrial subunits, Mutations, In-silico., OXPHOS, Breast cancer (BC), Ovarian cancer (OC). 
 
INTRODUCTION 
Mitochondria are double membranous, cytoplasmic semi-
autonomously functioning organelles. It is responsible for 
generating approximately 90% of cellular ATP through the process 
of oxidative phosphorylation (OXPHOS) and plays essential roles in 
cellular energy metabolism, free radical generation, and 
programmed cell death [1].  
Mitochondria contain its own genome which is a circular double 
stranded DNA of 16.6 kb in size. It encodes for 2 rRNAs, 22 tRNAs 
and 13 polypeptide [2]. All these 13 mitochondrial peptides, along 
with different nuclear encoded proteins, are integral subunits of 
different respiratory chain complexes Complex I has total 7 
mitochondrial encoded subunits (ND1-ND6 and ND4L), complex III 
has one (cytochrome b), complex IV has three (COX I-III) and 
complex V has two mitochondrial encoded subunits (ATPase6 and 
ATPase8).  
As compared to the nuclear DNA, mitochondrial DNA (mtDNA) is 
very much prone for mutations as it is known to lack histone 
proteins and DNA repair machinery [3]. Further, being a major site 
of ROS production, mtDNA is more vulnerable to oxidative damage 
and nucleotide changes. Thus because of all these factors, the 
reported mutations in mitochondria are 10-200 times more than 
nuclear DNA [3]. A large number of mutations in different protein 
regions of the mitochondrial genome are reported in association 
with different diseases including cancer too. 
In early 19th
Globally, BC comprises 16% of female cancers [11] and OC 
constitutes 20% of all genital malignancy accounting for more 
deaths than any other cancer of the female reproductive system 
[12]
 century, Otto Warburg hypothesized from his research 
that the malfunction in the mitochondria may cause an injury to the 
respiratory machinery, resulting in the compensatory ATP 
production through glycolytic pathway [4]. As the glycolytic 
pathway is less efficient than OXPHOS, thus cancerous cells would 
consume high glucose to fulfill their energy demand as compared to 
the healthy cells. It is considered as the important characteristic of 
cancerous cells [4-6]. It is proposed that mitochondrial dysfunction 
has been one of the major causes for aerobic glycolysis in the 
cancerous cells. Additionally, mutations in mtDNA are also proposed 
to cause high ROS production [6], which ultimately stimulates the 
cell proliferation and cancer progression. A large number of studies 
show the association between mutated mtDNA and risk of different 
types of cancers [7-9]. According to the WHO (World Health 
Organization) and WCRF (World Cancer Research Fund 
International), Breast cancer (BC), Cervix cancer and Ovarian cancer 
(OC) are commonly occurring cancers in women [10].  
. Cervical cancer is the most common genital cancer among 
females in developing country and accounts for 15% of all cancers in 
women [13]. Amongst all these three common cancer types in 
female, a large number of mutations in different regions of the 
mitochondrial genome are reported in BC and OC patients only. 
Association of these mtDNA mutations in BC and OC patients are 
suggested because of various studies involving amplification and 
sequencing of complete mitochondrial genomes of cancer patients 
and comparing the results to those obtained from non-cancerous 
tissues derived from the same patients [14]. As the number of these 
reported mutations is very high (109 in BC and 11 in OC), so it is not 
possible to functionally validate all these mutations by transmit 
chondrial studies. 
MATERIALS AND METHODS 
Hence it is imperative to do the initial analysis by 
In-silico methods. As this approach will help us to narrow down to 
few most potential pathogenic mutations, in-silico which will pave a 
path for future research to functionally validate them by using In 
vivo/In vitro model systems. However, till now there is no 
comprehensive study reported for highlighting the importance of 
these mt DNA mutations in cancer patients. Hence, our current study 
is an attempt to reveal the pathogenic nature of mtDNA mutations 
reported in protein coding region of BC and OC patients by using 
various in silico tools. 
Data collection  
Though a large number of mutations are reported all across the 
mtDNA in these BC and OC patients but we have done our analysis 
on protein coding mitochondrial subunit genes only and the 
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respective data were collected from various literatures and 
MITOMAP database. A total of 109 and 11 non-synonymous 
nucleotide changes across different protein coding mitochondrial 
genes, associated with the BC and OC, were included in the study 
[table 1].  
In-silico analysis 
In order to understand the effect of all these above-mentioned 
mutations on structure and function of respective mitochondrial 
protein, different bioinformatics tools have been used in this study. 
MUSCLE (M Ultiple sequence comparison by log-expectation) 
To analyze the significance of a specific mutation, its conservation 
across the higher to lower eukaryotes was explored using multiple 
sequence alignment tool MUSCLE. MUSCLE is claimed to achieve 
both better average accuracy and better speed than ClustalW2 or T-
Coffee. [http://www. ebi. ac. uk/Tools/msa/muscle/] 
Poly Phen-2 (Polymorphism Phenotyping v2) 
This is an automatic tool which uses the machine-learning approach 
for the prediction of possible impact of amino acid substitution on 
the structure and function of human protein. Prediction is based on 
straightforward rules which include sequence based 
characterization of substitution sites and structural parameters and 
contacts. The output of the tool predicts mutation to be either 
probably damaging i.e. mutation is supposed to affect with high 
confidence, possibly damaging i.e. mutation is supposed to affect but 
not with high confidence and benign i.e. mutation is not likely to 
produce any phenotypic effect. [http://genetics. bwh. 
harvard.edu/pph2/] 
SIFT (Sorting intolerant from tolerant) 
SIFT uses the approach of degree of conservation of amino-acids in 
the protein to predict the pathogenicity of the mutation. The tool 
assumes that the more conserved the site, more important the site 
becomes from the evolutionary perspective. It searches for closely 
related sequences through PSI-BLAST, performs multiple-sequence 
alignment, scans each position of the alignment and calculates the 
normalized probabilities for all 20 amino acids at that position. The 
output of the tool is a score between 0 to 1. Mutation is said to be 
damaging if the score is less than 0.05 and tolerable if score is 
greater than 0.05. SIFT also evaluates the confidence level of the 
prediction according to the diversity of the sequences taken for 
comparison. [http://sift.jcvi.org/www/SIFT_seq_submit2.html]. 
MUTPRED (Mut Pred) 
This tool predicts if the amino acid substitution in the respective 
protein is disease associated or neutral in nature. The output of 
MutPred contains a general score (g), i.e., the probability that the 
amino acid substitution is deleterious/disease-associated, and top 5 
property scores (p), where p is the P-value that certain structural 
and functional properties are impacted. Certain combinations of 
high values of general scores and low values of property scores are 
referred to as hypothesis. Scores with g>0.5 and p<0.05 are referred 
to as actionable hypotheses, g>0.75 and p<0.05 as confident 
hypotheses and g>0.75 and p<0.01 as very confident hypotheses. 
[http://mutpred. mutdb. org/]. 
MuPro 
To predict the possible impact of amino-acid substitution on the 
stability of the protein, MuPro was used. The tool is based on 
machine-learning approach including support vector machine (SVM) 
and artificial neural network (ANN) based on 20 pairs of testing and 
training datasets. Input can be either the amino-acid sequence or 
tertiary structure of the protein and the output is score between-1 
and 1. Score less than 0 indicates a decrease in stability of the 
protein and score greater than 0 indicates an increase in stability. 
Change in protein stability lead to altered contacts with other 
protein subunits, which is can be pathogenic. 
[http://mupro.proteomics.ics.uci.edu/]. 
PANTHER (Protein A nalysis through evolutionary relationships) 
It calculates the subPSEC (substitution position-specific 
evolutionary conservation) score based on an alignment of 
evolutionarily related proteins. subPSEC scores are continuous 
values from 0 to-10, where 0 implies a very conservative change 
which is unlikely to affect protein function, and more negative 
scores are increasingly damaging. A subPSEC score of less than-3, is 
taken as the cutoff value, indicating a high probability of substitution 
having a severe impact on the protein function [http:// 
www.pantherdb.org/tools/]. 
GOR4 
The Garnier–Osguthorpe–Robson (GOR) method analyzes sequences 
to predict the secondary structures of protein from amino acid 
sequence and classify it into alpha helix, beta sheet, turn, or random 
coil secondary structure at each position based on 17-amino-acid 
sequence windows. It takes into account the tendency of 
individual amino acids, along with its conditional probability to 
After doing in silico analysis of all 109 mutations [table1], 
Cytochrome B (CytB) subunit appears to be the major site for an 
accumulation of mutations in these patients as it was found to carry 
largest number of mutation (95 out of 109). However, a few 
numbers of mutations are also localized to different mitochondrial 
proteins which are integral component of different respiratory chain 
complexes such as complex I, IV and V. 
form 
particular secondary structures. [https://npsa-prabi.ibcp.fr/cgi-
bin/npsa_automat.pl?page=npsa_gor4.html]. 
RESULTS AND DISCUSSION 
Breast cancer 
 
Table 1: List of mitochondrial protein mutations reported in association with breast and ovarian cancer (Data obtained from mito map 
and literature) 
Cancer Type Mitochondrial subunits (No. of mutations) Nature of mutations 
1. Breast Cancer ND3 (1) T114A 
 ND4 (1) V381M,T337A 
 ND5 (1) N446K 













Taneja et al. 






 COX III (1) 
ATPase6 (8) 
F227I 
F6L, A11T, I14T, I24T, T53I, T59A, A177T, P187S 
 ATPase8 (1) T7A 
2. Ovarian cancer ND1(1) D248N 
 ND4(2) A131T,N424S 
 ND5(2) S523P,M1T 
 CytB (3) S213P,K217E,A302V 
 COX I(1) M417T 
 COX III (1) A95V 
 ATPase8 (1) P36L 
 
CytB  
Out of 95, a total of 28 mutations in CytB subunit are predicted to be 
pathogenic by the maximum of the tools used [table2]. All these 
mutations have shown to thermodynamically decrease the 
structural stability of the protein as predicted by MuPro. 21 out of 
these pathogenic mutations are found to affect the protein function 
as predicted by PolyPhen-2, SIFT and PANTHER. Similarly total 22 
mutations are predicted to cause a change in the overall percentage 
content of secondary structure in the protein at the specific position. 
The common secondary structure change seen was from coiled coil 
to helix and from helix to coil strand. 
  
Table 2: Reported non-synonymous mutations in protein-coding mitochondrial gene subunits associated with Breast cancer 
Mutati
ons 














ND3               
T114A B (0) Tol (0.86) Decrease Stability 
(-0.92) 





ND4               
V381M Prb (0.99) Affect (0) Decrease Stability 
(-0.44) 
No Impact Damaging  
(-4.10) 
c->e PC 
T337A Prb (0.99) Tol (0.13) Decrease Stability 
(-1) 





ND5               
N446K Prb (0.99) Affect (0.01) Decrease Stability 
(-1) 







CytB               
N263K B (0.02) Affect (0) Decrease Stability 
(-0.70) 





T264A B (0.20) Affect (0) Decrease Stability 
(-1) 
Actionable (loss of glycosylation) Damaging  
(-3.62) 
c->c C 
T264N Pos (0.64) Affect (0) Decrease Stability 
(-0.99) 
Actionable (loss of glycosylation) Damaging  
(-4.88) 
c->c C 
H267P Pos (0.47) Affect (0) Increased Stability 
(0.02) 
Actionable (gain of glycosylation) Not Damaging 
(-2.90) 
c->c C 
I268V B (0.01) Affect (0) Decrease Stability 
(-0.56) 
Actionable (Loss of catalytic residue)  Not Damaging 
(-2.79) 
c->c C 
P270T Prb(0.96) Affect (0) Decrease Stability 
(-0.92) 





E271A Pos (0.60) Affect (0) Decrease Stability 
(-0.12) 
No Impact Damaging  
(-4.32) 
c->c C 
E271G Pos (0.92) Affect (0) Decrease Stability 
(-1) 





E271D B (0.07) Affect (0) Increased Stability 
(+0.3) 





W272L Pos (0.94) Affect (0) Decrease Stability 
(-0.40) 





Y273N Prb (0.99) Affect (0) Decrease Stability 
(-1) 





Y273S Prb (0.99) Affect (0) Decrease Stability 
(-1) 





Y273C Prb (0.99) Affect (0) Decrease Stability 
(-0.93) 





F276V Pos (0.86) Affect (0) Increased Stability 
(0.34) 





F276L Pos (0.62) Affect (0) Increased Stability 
(0.09) 





T279A Error Tol (1) Increased Stability 
(1) 





L281R Prb (0.99) Affect (0) Decrease Stability Very Confident (gain of catalytic residue) Damaging  h- C 
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(-1) (-5.22) >c 
V284I Pos (0.51) Tol (1)  Decrease Stability 
(-0.38) 





N286D B (0.30) Affect (0) Increased Stability 
(0.31) 
No Impact Not Damaging 
(-2.47) 
c->c WC 
L288M B (0.37) Affect (0) Decrease Stability 
(-0.86) 





L288V B (0.03) Affect (0) Decrease Stability 
(-1) 
No Impact Not Damaging 
(-2.28) 
c->c NC 
G290S Prb (0.99) Affect (0) Decrease Stability 
(-1) 





L292V B (0.00) Affect (0.03) Decrease Stability 
(-0.15) 





L292R B (0.23) Affect (0) Decrease Stability 
(-0.65) 





L295V B (0.04) Tol (1) Decrease Stability 
(-0.37) 





L295W Pos (0.94) Affect (0) Decrease Stability 
(-0.67) 





S297F Prb (0.99) Affect (0) Increased Stability 
(+0.73) 





L299V B (0.13) Affect (0.02) Increased Stability 
(+0.29) 





L299F Pos (0.89) Affect (0) Decrease Stability 
(-0.54) 





L301M Pos (0.93) Affect (0) Decrease Stability 
(-0.19) 





M303V B (0.00) Tol (0.34) Decrease Stability 
(-0.64) 





M303T B (0.00) Affect (0.02) Decrease Stability 
(-1) 





M303I B (0.00) Tol (1) Decrease Stability 
(-0.67) 





I304M Pos (0.77) Tol (0.66) Decrease Stability 
(-0.68) 





P305A Pos (0.87) Affect (0) Decrease Stability 
(-0.27) 





I306V B (0.00) Affect (0.04) Decrease Stability 
(-0.21) 





I306M B (0.21) Tol (0.2) Decrease Stability 
(-0.62) 





H308L Pos (0.73) Affect (0) Decrease Stability 
(-0.29) 





H308E Prb (0.55) Affect (0) Decrease Stability 
(-0.67) 





M309L B (0.00) Tol (0.08) Increase Stability 
(0.10) 





M309T B (0.00) Tol (1) Decrease Stability 
(-1) 





S310P Prb (0.97) Affect (0) Decrease Stability 
(-0.25) 





K311N Pos (0.89) Affect (0.04) Decrease Stability 
(-0.45) 







M315L B Tol (0.08) Decrease Stability 
(-0.17) 





M316T B (0.00) Tol (0.1) Decrease Stability 
(-1) 





F317I Pos (0.89) Affect (0) Decrease Stability 
(-0.84) 





F317L Pos (0,62) Affect (0) Increase Stability 
(0.08) 





R318G Prb (0.99) Affect (0) Decrease Stability 
(-1) 





L320M Pos (0.70) Tol (0.09)  Decrease Stability 
(-0.24) 





S321N B (0.3) Affect (0) Decrease Stability 
(-0.46) 





L324I B (0.26) Affect (0.01) Decrease Stability 
(-0.76) 





L324F Prb (0,.96) Affect (0.01) Decrease Stability 
(-1) 





Y325H Prb (0.93) Affect (0)  Decrease Stability 
(-0.90) 





L327V B (0.00) Tol (0.17) Increase Stability No Impact Not Damaging h- NC 
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(0.17) (-2.30) >e,c 
L327P Pos (0.83) Affect (0) Decrease Stability 
(-1) 





L328R Pos (0.99) Affect (0) Decrease Stability 
(-0.26) 





A329G B (0.00) Affect (0) Increase Stability 
(0.1) 





A329V B (0.00) Tol (1) Increase Stability 
(1) 





A330T B (0.00) Affect (0) Decrease Stability 
(-1) 





D331G Prb (0.98) Affect (0) Decrease Stability 
(-1) 





L242R Prb (0.96) Affect (0) Decrease Stability 
(-1) 
Actionable (loss of stability, gain of 






L333F B (0) Tol(0.33) Decrease Stability 
(-0.75) 





L333H Pos (0.67) Affect (0) Decrease Stability 
(-0.92) 





I334L B (0.00) Affect (0) Decrease Stability 
(-0.72) 





L335Q Prb (0.99) Affect (0) Decrease Stability 
(-1) 





T336A B (0.29) Affect (0) Decrease Stability 
(-0.31) 





W337R Prb (0.99) Affect (0) Decrease Stability 
(-0.12) 





I338M Pos (0.49) Affect (0) Decrease Stability 
(-0.62) 
No Impact Damaging  
(-3.20) 
c->c PC 
Q341K B (0.34) Affect (0) Increase Stability 
(0.06) 
Actionable (gain of methylation, gain of 
ubiquitination) 
Not Damaging  
(-2.62) 
c->c NC 
V343E Pos (0.82) Affect (0) Increase Stability 
(0.74) 
No Impact Not Damaging  
(-2.10) 
c->c NC 
Y345H Pos (0.93) Affect (0) Decrease Stability 
(-0.48) 
No Impact Not Damaging  
(-1.31) 
c->c NC 
Y345D Pos (0.93) Affect (0) Decrease Stability 
(-0.19) 
No Impact Not Damaging  
(-1.32) 
e->c NC 
P346S Prb (0.99) Affect (0) Decrease Stability 
(-0.86) 
No Impact Not Damaging  
(-2.41) 
c->e C 
F347V Pos (0.91) Affect (0) Increase Stability 
(0.05) 
No Impact Damaging  
(-3.37) 
e->c NC 
F347C Prb (0.99) Affect (0)  Decrease Stability 
(-0.19) 
Actionable (gain of catalytic residue) Damaging  
(-4.88) 
e->c NC 
F347L Pos (0.73) Affect (1) Increase Stability 
(0.04) 
No Impact Not Damaging  
(-2.81) 
e->c NC 
T348N B (0.00) Affect (0)  Increase Stability 
(0.07) 





T348I B (0.00) Tol (1) Increase Stability 
(0.63) 





I349T B (0.00) Tol (0.32) Decrease Stability 
(-1) 
No Impact Not Damaging  
(-2.07) 
c->e NC 
I350M Pos (0.86) Affect (0) Decrease Stability 
(-0.61) 
No Impact Not Damaging  
(-2.82) 
c->e C 
V353E Pos (0.93) Affect (0) Increase Stability 
(0.19) 





A354V Prb (0.99) Affect (0) Increase Stability 
(0.60) 
No Impact position not 
align 
c->e NC 
L357M Pos (0.81) Tol (0.08) Decrease Stability 
(-1) 
No Impact position not 
align 
c->e NC 
L357V B (0.20) Affect (0) Decrease Stability 
(-1) 
Actionable (gain of catalytic residue) position not 
align 
c->e NC 
T360A B (0.10) Tol (0.25) Decrease Stability 
(-0.10) 





T361M Pos (0.96) Affect (0.01) Increase Stability 
(1) 





I362V B (0.01) Affect (0.01) Decrease Stability 
(-0.48) 
No Impact position not 
align 
c->e NC 
L363R Prb (0.96) Affect (0)  Decrease Stability 
(-0.89) 
No Impact position not 
align 
c->e NC 
I364L B (0.00) Tol (0.22)  Decrease Stability 
(-0.92) 
No Impact position not 
align 
c->e NC 
I364F B (0.00) Tol (0.09) Decrease Stability 
(-1) 
No Impact position not 
align 
c->e NC 
L365V B (0.10) Affect (0.01) Decrease Stability No Impact position not e->c PC 
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M366L B (0.00) Tol (0.11) Decrease Stability 
(-1) 
No Impact position not 
align 
e->c NC 
M366I B (0.00) Affect (0) Decrease Stability 
(-1) 
No Impact position not 
align 
e->c NC 
T368N B (0.01) Affect (0) Decrease Stability 
(-0.28) 





T368I B (0.00) Tol (1) Increase Stability 
(0.74) 
No Impact position not 
align 
e->c NC 
COX III               
F227I Prb (0.99) Affect (0.05) Increase Stability 
(0.48) 





              
F6L Prb (0.97) Affect (0.03) Decrease Stability 
(-0.40) 
No Impact Damaging  
(-3.45) 
c->c PC 
A11T B (0.00) Tol (0.77) Decrease Stability 
(-1) 
No Impact Not Damaging  
(-2.25) 
c->c NC 
I14T Pos (0.74) Affect (0.01) Decrease Stability 
(-1) 
Actionable (loss of stability) Not Damaging  
(-2.23) 
c->e PC 





I24T Prb (0.99) Affect (0.01) Decrease Stability 
(-1) 





T59A B (0.00) Tol (0.64) Decrease Stability 
(-1) 
No Impact does not align  e-
>h 
NC 
A177T Pos (0.91) Tol (0.16) Increase Stability 
(0.05) 





P187S B (0.04) Tol (0.25) Decrease Stability 
(-1) 







              
T7A B (0.00) Affect (0.01) Decrease Stability 
(-1) 
No Impact Not Damaging  
(-1.75) 
e->c NC 
B: Benign, Prb: Probably damaging, Pos: Possibly damaging, Tol: Tolerable, c-random coil, e-extended sheets, h-helix, NC: Non-Conserved, PC: 
Partially Conserved, WC: Weakly Conserved, C: Conserved 
 
Out of important mutations, change at 264 position (T264A, T264N), 
cause the substitution from Threonine to Alanine and Aspargine, 
which is strongly conserved in position. As this change is from polar, 
hydrophilic to hydrophobic amino acid, may lead to the improper 
protein folding. Loss of glycosylation which is predicted by MutPred 
and MuPro, may further affect the protein-protein interaction and 
decrease the stability of protein. However, there is no change in the 
secondary structure. 
Amino-acid position 273 is conserved across species and there are 3 
mutations (Y273N, Y273S, Y273C)which cause change from 
Tyrosine (aromatic) to Asparagine, Serine or Cysteine in different 
patients of BC. Although GOR4 shows no secondary structure change 
except in Y273C, but all 3 are predicted to have a functional impact 
as predicted by PolyPhen-2, SIFT and PANTHER as well as a major 
decrease in stability, predicted by MuPro.  
L281R mutation causes a change from a neutral, non polar amino 
acid Leucine to a polar, strongly basic amino acid Arginine which 
may affect the charge distribution on the surface of the CytB protein 
at the specific position. The result of MuPro also supported the same 
by predicting this change to decrease the stability of the protein. 
Moreover, according to MutPred, the mutation caused a gain of 
catalytic residue which may possibly alter the rate of the catalytic 
reaction. This mutation seems to be critical as on one hand it is 
suggested to be damaging by in-silico tools in the study and on the 
other hand it affects the secondary structure from helix to coil. The 
importance of the position was also shown by its evolutionary 
conservation. 
On the other hand, though L242R, L288M, L292R, L328R mutations 
are not present at conserved positions but predicted to be damaging 
with a decrease in stability. Leucine is a hydrophobic amino acid and 
Arginine is polar, positively charged which might change the ionic 
environment around the protein at the specific position. Methionine, 
otherwise being fairly non-reactive but has a propensity to be found 
in the helical structures, and further hence L288M, L328R, L242R 
predicted to cause change the secondary structure from coil to helix. 
For all the mutations, MutPred predicted very opposite effects i. e 
loss of methylation in L288M and gain of methylation in case of 
L292R whereas PolyPhen-2 predicted it as Benign. PANTHER 
showed a damaging effect of mutations for L242R and L328R. 
The three mutations P270T, E271G, S310P have almost similar 
damaging effect on Cyt B protein since in both the cases there is a 
change between polar and non-polar nature of amino acids. The 
substantial reduction in stability in case of P270T might be due to 
the branched side chain of Threonine causing steric collisions and 
destabilizing the protein structure, whereas in case of E271G, charge 
difference between acidic Glutamic acid and neutral small Glycine 
may be the causing factor. Also, since E271G causes a secondary 
structure changes from helix to extended sheet and coil, it might 
cause altered rigidity/flexibility in the protein structure at specific 
site. 
Both the changes W272L and F317I are predicted to be damaging 
and unstable which is supported by the fact that Phenyl alanine, 
Tryptophan being aromatic occupies a larger space than Leucine, 
and hence the extent of interaction with its neighboring residues 
might get affected. Moreover, helical confirmation is changed to coils 
and sheets as predicted by GOR4.  
The importance of G290S mutation lies in the fact that Glycine is 
unique in having much more conformational flexibility than any 
other amino acid, due to which it can reside in parts of protein 
structures forbidden to all other amino acids. This means that 
substitution of a conserved Glycine residue with Serine change could 
have a drastic impact on function. The tools strongly supported this 
with a high score value.  
In case of mutations H308E, K311N and R318G, both K311N and 
R318G were found to drastically affect the stability of protein except 
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H308E. However, for H308E and K311N mutations, MutPred 
predicted to cause ubiquitination of protein. Ubiquitin moieties are 
responsible for directing the protein to degradation pathway. 
Additionally, Histidines are the most common amino acids present 
in active/binding site of proteins so its loss at the specific position in 
protein might affect the catalysis process of substrate. On the similar 
lines, all these three substitutions were indicated damaging by 
PolyPhen-2 and SIFT too. As a result of L324F mutation, non-polar 
aliphatic amino acid Leucine is being changed to aromatic 
Phenylalanine. Leucine is known to be the strong helix-favoring 
residues because of long side chains, whereas in Phenylalanine side 
chains are branched due to which it prefers to be in β sheets [15]. 
This is correctly supported by the tool GOR4 which predicted the 
change from helix to extended sheets. Also, this might cause steric 
hindrance to interactions with other protein subunits. Moreover, it 
is also proposed to decrease the stability of protein and loss of 
catalytic residue by the tools of our study  
Y325H mutation is not present at conserved position, but still 
proposed to be deleterious by in-silico tools. Tyrosine residues, 
being involved in phosphorylation events by various kinases and 
play an important role in protein function. Therefore, its 
substitution by Histidine may account for its damaging effects. Also, 
there is a substantial decrease in stability which may be due to 
change in aromatic to aliphatic amino acid. As per GOR 4, the helical 
structure at this position is predicted to be converted in both coil 
and extended sheet with equal probability. In case of mutations 
L327P, I350M both amino acids belong to the same neutral, non-polar 
category. Mur Pred did not predict this change to be deleterious, but 
PolyPhen-2 and SIFT suggested it to be pathogenic, L327P was further 
predicted damaging by PANTHER too.  
D331G is a change from polar, acidic Aspartic acid to non-polar, 
neutral Glycine. Tools used in the study have suggested it to be 
pathogenic. The wide difference between the hydrophobicity and 
size of Aspartic acid and Glycine may account for the pathogenic 
nature of this mutation. The negative charge of Aspartic acid means 
that it can interact with metallic ions carrying opposite charge, while 
change to Glycine may affect the molecular interactions. This may be 
the possible explanation towards the decreased stability of the 
protein which is also supported by the MutPred.  
By looking at the scores of PolyPhen-2 and SIFT, L333H and L335Q, 
have similar damaging effects on the protein structure and function. 
Also, both mutations are causing decrease in stability with 
comparable scores which is supported by Mut Pred with an 
actionable hypothesis of loss of stability. This can be explained, on 
the basis of the fact that Leucine (small, non-polar molecule) is 
substituted with Histidine or Glutamine, which are polar in nature 
and hence will have altered tendency to form bonds with 
neighboring amino acids. Due to change in nature of amino acids, 
secondary structure is also changed with respect to these mutations.  
The W337R mutation replaces Tryptophan by Arginine. As, 
Tryptophan has very hydrophobic aromatic side chains, so its 
replacement with polar strongly basic Arginine might be disastrous 
at that particular conserved position. This is completely supported 
by the tools which predicted it to be damaging. Because of this 
mutation, a regular helical conformation is converted to random coil 
and the reason might be loss of stacking interactions by the aromatic 
amino acids. Based on the confident hypothesis of MutPred, this 
mutation is also found to result in loss of catalytic residue. 
F317I and F347C both resulted in a change from aromatic to 
aliphatic amino acid which might account for its damaging effect. 
Isoleucine is more restricted in conformation of it’s main chain and 
hence prefers to lie within β sheets. Favoring it, GOR4 predicts 
change in secondary structure of protein from helix and coil to 
extended sheets due to F317I mutation. While the mutation F347C is 
not present at conserved position and almost neutral in its influence 
on protein’s stability, F317I is predicted to result in substantial 
decrease in stability and also found at conserved position. Both the 
mutations are hypothesized to cause gain of catalytic residue, which 
may further alter enzyme activity. 
 
Table 3: Reported non-synonymous mutations in protein-coding mitochondrial gene subunits associated with ovarian cancer (OC) 
Mutati
ons 










ND1               
D248N Error Tol (0.79)  Decreased Stability (-0.27) No Impact Not Damaging (-1.11) c->c NC 
ND4               
A131T B (0.03) Tol (0.05) Decreased Stability (-0.55) No Impact Position not align e->e NC 
N424S B (0.00) Tol (0.42) Decreased Stability (-0.16) No Impact Not Damaging (-2.48) c->c NC 
ND5               
S523P Error Tol (0.08) Increased Stability (0.37) No Impact Damaging (-4.16) e->c NC 
M1T Score not 
available 
Affect (0.00) Decreased Stability (-0.45) confident (gain C. R, loss 
stability), very conf (gain 
glycosylation) 
Position not align e->c NC 
CytB               
S213P Pos (0.95) Affect (0.00) Decreased Stability (-0.11) No Impact  Damaging (-3.24) e->c WC 
K217E Pos (0.60) Affect (0.00) Decreased Stability (-0.11) No Impact Damaging (-3.79) e->c C 
A302V B (0.03) Tol (0.12) Increased Stability (0.22) No Impact Not Damaging (-2.08) h->h NC 
COX I               
M417T Error Tol (0.64) Decreased Stability (-1) No Impact Not Damaging (-1.88) e->c NC 
COX III               
A95V B (0.00) Tol (1) Increased Stability (1) No Impact Not Damaging (-1.26) c-e NC 
ATPase
8 
              
P36L B (0.00) Tol (0.23) Decreased Stability (-0.42) No Impact Not Damaging (-2.12) h,c-e NC 
B: Benign, Prb: Probably damaging, Pos: Possibly damaging, Tol: Tolerable, c-random coil, e-extended sheets, h-helix, NC: Non-Conserved, PC: 
Partially Conserved, WC: Weakly Conserved, C: Conserved 
 
ATpase6 and ATpase8 
Apart from a large number of mutations in CytB subunit, a total of 8 
and 1 nucleotide changes are also reported in ATPase6 and ATPase8 
subunits of BC patients, respectively (Supplementary table1). F6L 
and I14T of ATPase6 were suggested pathogenic by most of the in-
silico tools used in our study. Though Phenylalanine and Leucine 
both are hydrophobic and hence buried in protein core but 
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substitution of an aromatic compound by aliphatic amino acid might 
account for the damaging effect of F6L mutation. Isoleucine is also 
non-polar whereas Tyrosine is polar-aromatic compound containing 
a reactive hydroxyl group, thus making it much more likely to be 
involved in interactions with non-carbon atoms [16]. Although 
PANTHER score was less for this mutation, it is hypothesized as 
actionable due to loss of its stability. Furthermore, it changed the 
secondary structure from coil to extended sheets which may provide 
rigidity to the protein. In I24T mutation of ATPase6, both amino 
acids are hydrophobic in nature and found to be buried in protein 
core. The mutation is not present at conserved position and is not 
found to have any molecular impact or change in secondary 
structure. But since Isoleucine is aliphatic and Tyrosine is aromatic, 
this may have resulted in decrease in the protein stability as 
predicted by MuPro. 
ND3, ND4 and ND5 
Mitochondrial subunits such as ND3, ND4 and ND5 which are 
components of respiratory chain complex I also have limited 
number of mutations in BC patients and most of them are not 
predicted to affect the respective proteins. For example, mutations 
such T114A (ND3) and T337A (ND4) are not found to affect the 
proteins, but V381M in ND4 is predicted to affect the stability of the 
protein as per MuPro. The mutation is also suggested to affect the 
protein by PolyPhen-2, SIFT and PANTHER as well as causes change 
in the secondary structure from coil to extended sheet. Similarly 
N446K (ND5)
Mutations and altered expression of the mtDNA encoded proteins 
have been observed in various tumours and appears to be a general 
feature of the cancerous cells. Though various studies have focused 
on identification and characterization of these alterations but have 
limited insights to its functional and clinical consequences especially 
when there is large number of mutations reported. Our study 
highlights the pathogenic importance of different mitochondrial 
protein mutations in case of BC and OC. As per our analysis, out of all 
the protein coding mitochondrial genes, CytB gene seems to carry 
largest number of pathogenic mutation (28) in BC. All these 
mutations of CytB are predicted to affect the protein in different 
manner which may ultimately alter the activity of complex III 
enzyme. On the basis of our vigorous analysis and predictions made 
by various in-silico tools, some most important mutations, which are 
predicted to significantly pathogenic are T264A, T254N, P270T, 
E271G, W272L, Y273N, Y273S, Y273C, L281R, L288M, G290S, 
L292R, H308E, S310P, K311N, F317I, R318G, L324F, Y325H, L327P, 
L328R, D331G, L242R, L333H, L335Q, W337R, F347C, I350M in BC 
All these selected mutations may be further analyzed for its 
functional relevance in in-vitro system. Apart from CytB, mutation in 
other mitochondrial subunits did not show such a high level of 
significance. The total number of mitochondrial gene mutations is 
very limited in case of OC patients, however the maximum number 
of mutations which are predicted to be significantly pathogenic are 
again localized to CytB only. S213P and K217E are two mutations in 
CytB which are predicted to be highly pathogenic in OC. It is 
conceivable that mtDNA variants (especially CytB) might play very 
important role in influencing the risk of BC and OC risk. New 
prognostic markers of BC metastasis are urgently needed to avoid 
overtreatment or under treatment of newly diagnosed patients. This 
knowledge will allow the development of new diagnostic methods, 
which might lead to more effective intervention strategies for 
BC and OC. 
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